I
Ilya Pharma
Ilya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract
About Ilya Pharma
Developer of next-generation biological drugs designed to treat wounds in skin and mucosa. The company's biological drug is a novel drug delivery system where lactic acid bacteria are used as vectors to produce and deliver biological drugs on-site to skin wounds or in the gastrointestinal tract, its human therapeutic proteins are delivered on-site in wounds by living lactic acid bacteria acting like small bioreactors, enabling patients with diabetes to get accelerated healing of a chronic wound in a cost-effective way. Keywords: Pharmaceuticals and BiotechnologyBiological Drug Developer, Biological Drugs, Biological Drugs Developer, Healthcare Delivery, Human Therapeutic Protein, Local Immunotherapy, Local-Acting Immunotherapy, Wound Healing Drugs, Wound Treatment.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Uppsala kommun, Sweden
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
EIT Health
European Innovation Council
Series A1 investor entered at this stage
EIC Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ilya Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ilya Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.